康诺亚-B(02162)现涨近7%，截至发稿，涨6.59%，报41.25港元，成交额5655.01万港元。

消息面上，4月4日，司普奇拜单抗治疗SAR III期临床研究成果在Nature Medicine上发表，这是全球首个披露阳性数据的IL-4Rα单抗治疗SAR研究。该研究发现，对于经常规治疗仍未控制的中重度季节性过敏性鼻炎患者，新型生物制剂司普奇拜单抗可显著改善其临床症状及生活质量。

华泰证券指出，过敏性鼻炎未满足需求庞大，司普奇拜单抗疗效优异。鉴于该品种在SAR及CRSwNP两项鼻科适应症目前为国内独家获批，且在AD适应症中疗效安全性具BIC潜力，持续看好司普奇拜单抗的销售前景。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.